


# IVUS Assessment of the Mechanism of In-stent Restenosis?

*Gary S. Mintz, MD*

*Cardiovascular Research Foundation*


# SURE Trial: Restenosis in non-stented lesions

Average of the two image slices with the smallest pre-intervention and follow-up lumen CSA




61 native vessel lesions (26 DCA, 35 PTCA) with complete serial IVUS studies (out of 79 lesions enrolled in the study)

# Restenosis in Stented Lesions




# Therefore, in-stent restenosis is all intimal hyperplasia

$\Delta$ lumen CSA (mm<sup>2</sup>)



$\Delta$ Stent CSA (mm<sup>2</sup>)


$\Delta$ lumen CSA (mm<sup>2</sup>)





IH CSA (mm<sup>2</sup>)





POST



F/U




# Analysis of 1089 Consecutive Patients With Bare Metal In-stent Restenosis



**4.4% of cases had "unrecognized mechanical complications"**  
**12% had severe chronic stent underexpansion (<4.5mm<sup>2</sup>)**

# Impact of lesion length and final minimum stent area (MSA) on restenosis




*\*No actual observations in this range*

# Predictors of DES Thrombosis & Restenosis

	DES Thrombosis	DES Restenosis
<b>Underexpansion</b>	<ul style="list-style-type: none"> <li>• Fujii et al. <i>J Am Coll Cardiol</i> 2005;45:995-8)</li> <li>• Okabe et al., <i>Am J Cardiol.</i> 2007;100:615-20</li> <li>• Liu et al. <i>JACC Cardiovasc Interv.</i> 2009;2:428-34</li> </ul>	<ul style="list-style-type: none"> <li>• Sonoda et al. <i>J Am Coll Cardiol</i> 2004;43:1959-63</li> <li>• Hong et al. <i>Eur Heart J</i> 2006;27:1305-10</li> <li>• Doi et al. <i>JACC Cardiovasc Interv.</i> 2009;2:1269-75</li> <li>• Fujii et al. <i>Circulation</i> 2004;109:1085-1088</li> <li>• Rathore et al. <i>EuroIntervention</i> 2009;5:349-54.</li> </ul>
<b>Edge problems (geographic miss, secondary lesions, large plaque burden, etc)</b>	<ul style="list-style-type: none"> <li>• Fujii et al. <i>J Am Coll Cardiol</i> 2005;45:995-8)</li> <li>• Okabe et al., <i>Am J Cardiol.</i> 2007;100:615-20</li> <li>• Liu et al. <i>JACC Cardiovasc Interv.</i> 2009;2:428-34</li> </ul>	<ul style="list-style-type: none"> <li>• Sakurai et al. <i>Am J Cardiol</i> 2005;96:1251-3</li> <li>• Liu et al. <i>Am J Cardiol</i> 2009;103:501-6</li> <li>• Costa et al, <i>Am J Cardiol,</i> 2008;101:1704-11</li> </ul>


## Cypher in SIRIUS\*




IVUS MSA (mm<sup>2</sup>)

By definition, sensitivity/specificity curve analysis "must" identify a single MSA that best separates restenosis from no restenosis. This does NOT mean that 5.0-5.5mm<sup>2</sup> suffices in all pts/lesions.

## Cypher at AMC\*\*



Angiographic restenosis (%)



IVUS MSA (mm<sup>2</sup>)

TAXUS-IV, V, VI and ATLAS WH, LL, and DS (c-statistic=0.64)\*\*\*

\*Sonoda et al. J Am Coll Cardiol 2004;43:1959-63

\*\*Hong et al. Eur Heart J 2006;27:1305-10


\*\*\*Doi et al. J Am Coll Cardiol Intv 2009 2: 1269-75

Honda & Fitzgerald. J Am Coll Cardiol Intv 2009 2: 1276-8




# Predictors of angiographic restenosis in 550 pts with 670 native lesions treated with Cypher stents

Angiographic restenosis (%)




Angiographic restenosis (%)



	<5.5mm <sup>2</sup>	≥5.5mm <sup>2</sup>
≤40mm	2.4%	0.4%
>40mm	17.7%	8.6%

# The Optimal Cutoff Value of Post-Procedural MSA to Predict a Follow-up MLA $\geq 4\text{mm}^2$ After Bifurcation T-Stenting





**AUC=0.88**  
**(95%CH=0.80-0.95)**


**AUC=0.81**  
**(95%CH=0.64-0.99)**

# Manufacturer's Compliance Charts Cannot Be Used to Guarantee Adequate Stent Expansion

Comparison of IVUS-measured minimum stent diameter (MSD) and minimum stent area (MSA) with the predicted measurements from Cordis (Cypher in yellow, n=133) and BSC (Taxus in red, n=67). DES achieve an average of only 75% of the predicted MSD (66% of MSA)



# Comparison of 9-month QCA edge restenosis vs reference lumen area and plaque burden in TAXUS-IV, V, and VI (n=810)



# Underexpansion is often lumped with malapposition - even by people who should know better

## Stent Thrombosis – No single set of predictors

	JEREMIAS (registry)	IAKOVU (registry)	MORENO (RCT's)	e-CYPHER (registry)	ARRIVE 1 (registry)	Cheneau et al. (registry)
Advanced age				Yes		
Plav Non-compliance	Yes	Yes				
Diabetes		Yes		Yes	Yes	
ACS/AMI				Yes		
Renal failure		Yes				
Low LVEF		Yes				
Bifurcation		Yes				
Calcifications				Yes		
Total occlusion				Yes		
MVD				Yes		
Total stent length			Yes			
Malapposition						Yes
Number of stents			Yes			

AMI = acute myocardial infarction; LVEF = left ventricular ejection fraction; RCT = randomized clinical trial; MVD = multivessel disease.  
 Modified from Urban, EuroPCR, 2006. Oral presentation; Cheneau et al. *Circulation* 2003; 108:43.

41

## Summary


- **Stent thrombosis is multifactorial**
  - Anatomic, clinical, pharmacologic
- **Early stent thrombosis (~ 0.6%) is related to:**
  - Lesion complexity
  - Stent malapposition
  - Variable anti-platelet agent responsiveness
  - Early discontinuation of anti-platelet therapy (strongest risk factor)
- **LST and VLST are rare but serious complications of DES**
  - It was not seen in patients who remain on dual anti-platelet therapy in the RESEARCH/TSEARCH analysis by Ong et al, or the TAXUS meta-analysis (1 patient only)
- **Current ESC PCI guidelines now recommend 6-12 months of dual anti-platelet therapy after DES**
  - The TAXUS® Express2™ DFU recommends 6 months of dual anti-platelet therapy

48


# Acute Incomplete DES Apposition and IH

- Persistent ISA (n=40, 83% decreased in size)
- Completely resolved ISA (n=15)

CSA (mm<sup>2</sup>)



CSA (mm<sup>2</sup>)



Persistent stent malapposition is associated with less intimal hyperplasia – the drug can cross small stent vessel-wall gaps


(Hong et al. *Circulation* 2006;113:414-9)

(Kimura, et al. *Am J Cardiol* 2006;98:436-42)

(Balakrishnan et al., *Circulation* 2005;111:2958-65)


# Serial angiographic FU of Palmaz-Schatz stents

**3 yr FU**




*Kimura et al., N Engl J Med 1996;334:561-6*

**Extended FU (7 - 11 yrs)**




*Kimura et al., Circulation 2002;105:2986-91*



# Changes in Maximum Yellow Color Grade From Baseline to Follow-Up in DES









# Percentage of Patients With Atherosclerotic Changes in DES Versus BMS in Relation to Duration of Implant at Autopsy



# *BMS 57-month follow-up*




# Analysis of 20 stent fractures in 17 patients




- 15 stent fractures were detected by angiography and IVUS, and 5 were detected only by IVUS
- 15 stent fractures in 13 patients were associated with in-stent restenosis (all focal); and 2 stent fractures in 2 patients were associated with very late stent thrombosis
- Five stent fractures occurred within a coronary aneurysm accompanied by malapposition despite the absence of a coronary aneurysm at index stenting.
  - Comparing stent fractures associated with an aneurysm to ones that did not occur in association with an aneurysm, complete stent fracture was more frequent (100% vs. 27%,  $p=0.008$ ), and all presented  $>1$  year after index stenting (vs. 33%,  $p=0.03$ ).

# Assessment of causes of in-stent restenosis


Baseline




Follow-up




**A**




**B**




**C**



**D**




**E**





**diastole**

**systole**

**diastole**









0 → 2.5 → 12.5mm



0 —————> 5.0 —————> 15.0mm














0

→2.5


→10.0mm



**DES after VBT  
failure for Rx of  
BMS Restenosis**



**2 years later**



# 9-month minimum lumen area that predicts 3-year MACE-free survival in patients from TAXUS IV, V, and VI

<b>n=348</b>	<b>BMS</b>	
	<b>C-statistic</b>	<b>Cutoff</b>
<b>Minimum lumen area</b>	<b>0.73</b>	<b>4.0mm<sup>2</sup></b>

<b>n=351</b>	<b>Taxus</b>	
	<b>C-statistic</b>	<b>Cutoff</b>
<b>Minimum lumen area</b>	<b>0.75</b>	<b>4.2mm<sup>2</sup></b>